Human Longevity and LEV Foundation will study centenarians’ blood to understand why some people stay healthier for longer.
In longevity biotech, there is a recurring temptation to look forward to the next drug, the next platform, the next breakthrough. However, sometimes, the most revealing clues are already here, quietly embodied by the oldest people among us.
That is the premise behind a newly announced collaboration between California-based biotech Human Longevity, Inc. (HLI) and non-profit organization LEV Foundation (LEVF), which will study blood samples from centenarians and supercentenarians in an effort to understand the biological drivers of exceptional longevity [1].
Put simply, the two organizations are asking a question: why do some people appear to age more slowly than others? It is one with real weight for investors and for the broader longevity sector. If researchers can identify what makes certain individuals stay healthier for longer, the payoff could extend far beyond academic curiosity. It could shape future diagnostics, prevention strategies and, eventually, therapeutics aimed at extending healthspan.
Centenarians (people who live past 100) and supercentenarians (those who reach 110 and beyond) are often treated like statistical marvels. But in longevity science, they are a rare source of biological evidence.
In a field crowded with mouse data and ambitious claims, these individuals offer something unusually grounded. They are not theoretical models. They are proof that, under certain circumstances, the human body can remain resilient far deeper into old age than the norm.
This collaboration stands out because rather than building another longevity narrative around prediction alone, HLI and LEVF are going directly to the people who may already hold part of the answer. Their blood samples, the companies say, could reveal molecular and cellular patterns that help explain why some individuals avoid or delay the typical wear-and-tear of aging.
Think of it like this: if aging is a long road, centenarians may be the people who somehow found a smoother route. Researchers now want to study the map.
The technical language around this project includes terms like genomics, proteomics and “multi-omic analysis,” which can sound like the sort of jargon that sends ordinary readers sprinting in the other direction. But the underlying concept is surprisingly intuitive.
Instead of looking at just one aspect of biology, researchers examine many layers at once. Genes are one layer. Proteins are another. Other measurable signals in the blood add more context. It is less like glancing at a single lab result and more like reading an entire dossier on how a body is functioning behind the scenes. Or, to put it more simply: they are not just checking one dashboard light; they are lifting the hood.
HLI plans to use its AI-driven precision longevity platform to help process and interpret that information. The aim is to identify biomarkers and pathways associated with exceptional longevity – measurable signs and biological processes that appear to be present in people who age unusually well.
From there, the bigger ambition is translational. If those patterns can be confirmed, they may help inform tools that detect risk earlier, guide more personalized prevention, or support future therapies that keep people healthier later in life.
That is where the story loops back to longevity in its most practical sense. Longevity biotech is increasingly being asked to prove that it can move beyond broad aspiration and into evidence-based, human-relevant insight. This collaboration feels aligned with that shift. It is not just another declaration that aging is modifiable. It is an attempt to anchor that belief in a very specific and unusually valuable population.
Dr Wei-Wu He, the Executive Chairman at Human Longevity, Inc, explained that individuals who live to 100 or older provide unique, natural perspectives on the aging process. He noted that by using the company’s precision longevity platform to study those with exceptional lifespans, researchers can gain a deeper understanding of how to maintain health in old age for the general population.
Ultimately, He emphasized that the insights gathered from this research could fundamentally transform the current medical approach to aging and the management of age-related diseases.
Dr Aubrey de Grey, the President and Chief Science Officer at LEVF, expressed his enthusiasm regarding the partnership with HLI, noting that the collaboration aligns with the objectives of both organizations. He emphasized that studying the oldest members of society offers invaluable insights to refine the preventative medical treatments for age-related chronic conditions originally pioneered by HLI.
Moreover, de Grey remarked that this research provides a vital complement to LEVF’s work with murine models, and he expressed confidence that the resulting synergy between the two entities will ultimately save many lives.
It is also notable that both Aubrey de Grey and Natalie S Coles-de Grey are joining HLI’s scientific advisory board, adding further strategic alignment to the collaboration.
Of course, there is a reason these individuals are called exceptional. Their biology may not be easy to replicate. What works in a person who reaches 110 may not translate neatly into a therapy for the average 60-year-old with metabolic disease, cardiovascular risk or cognitive decline.
It’s the kind of nuance investors should keep in mind. Exceptional longevity does not automatically equal commercializable longevity. A fascinating biomarker is not the same as a viable drug target. A compelling dataset is not yet a product. And in this field, the distance between scientific intrigue and scalable intervention can still be vast.
Nonetheless, that does not diminish the importance of the work. If anything, it sharpens it. Because in a sector that can sometimes sound a little too eager to sell the future, the smartest move may be to study the people who have already lived it. And if longevity biotech truly wants a map for where healthier aging could go next, the oldest old may be the most credible place to begin.
